VeriChip Infant Protection Product Now Used in One-In-Three U.S. Hospitals and Birthing Centers
National Stroke Association Views Implantable RFID Microchip such as VeriMed as a Potential Life-Saving Medical Device
Over 1,100 Installations To-Date in the United States
DELRAY BEACH, Fl.
— December 11, 2006 — Applied Digital (Nasdaq: ADSX - News), through its VeriChip Corp. subsidiary, announced today that it has passed an important milestone in the sale and use of VeriChip's infant protection systems, with one-out-of-three Hospitals and Birthing Centers in the United States now using systems manufactured by VeriChip. This includes systems sold under both the Hugs and HALO brand names.VeriChip believes that it has the largest installed base of infant protection systems of any company in the industry. Revenues from sales of VeriChip's infant protection systems increased by 28% during the first three- quarters of 2006 as compared to pro forma revenue from such systems during the comparable period in 2005. "This important achievement is reflective of VeriChip's leadership in RFID products for healthcare security solutions," said Daniel A. Gunther, President of VeriChip Corp.
VeriChip Announces Results of Italian National Institute Two-Year Clinical Study of VeriMed System
In a letter to VeriChip Corporation, a subsidiary of Applied Digital Solutions (Nasdaq: ADSX), the National Stroke Association (NSA) has recognized that implantable RFID microchip technology offers the ability to improve stroke treatment by providing medical professionals with immediate access to vital health information of stroke-afflicted patients. An excerpt from the letter, signed by James Baranski, CEO of the National Stroke Association, states, "Personal Health Records, including implantable RFID microchips such as VeriMed, could play a critical role in assisting medical professionals in delivering appropriate stroke treatment promptly, leading to better patient outcomes."
See... A generation is all they need...pretty much sums it up!
The two-year, 10 patient study was designed to evaluate the safety and efficacy of the VeriMed implantable RFID microchip and the functionality of the VeriMed System in the management of patients with chronic infectious diseases undergoing care at the Institute. The study reported no complications or side effects related to the insertion procedure, flawless access of the ID number using the hand-held reader, and universal acceptance within the patient study group. Based on the results of the study, the exclusive VeriChip distributor for Italy plans to petition the Italian Ministry of Health for full availability of the VeriMed System through the Italian National Health Service.